LTBI Treatment and Anti TNF alpha

Similar documents
10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

TUBERCULOSIS AND THE TNF-α INHIBITORS. Lloyd Friedman, M.D. Yale University Milford Hospital

Tuberculosis and Biologic Therapies: Risk and Prevention

TB Update: March 2012

TB Classification (ATS/CDC)

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB

Latent TB Infection Treatment

State of the State in TB Control

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:

ESCMID Online Lecture Library. by author

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016

Tuberculosis Update. Topics to be Addressed

TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of

Diagnosis and Medical Management of Latent TB Infection

TB in the Patient with HIV

Treatment of Latent TB Infection (LTBI)

Santa Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, 2014

Latent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal

Communicable Disease Control Manual Chapter 4: Tuberculosis. Assessment and Follow-Up of TB Contacts

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Pediatric Tuberculosis in Los Angeles County: An Update

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013

TB in Corrections Phoenix, Arizona

Tuberculosis Education for the Medical Professional

Contact Investigation and Prevention in the USA

Tuberculosis Tools: A Clinical Update

Errors in Dx and Rx of TB

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

Screening and Treatment Recommendations for Persons Exposed to MDR TB

Latent TB Infection (LTBI)

Northwestern Polytechnic University

Tuberculosis in Non-HIV Infected Immunosuppresed Hosts. TNFα inhibitors and beyond

Latent TB, TB and the Role of the Health Department

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH

Jennifer Lam MPH candidate 2009 Johns Hopkins Bloomberg School of Public Health. Preceptors: Wendy Cronin, PhD MT(ASCP), Cathy Goldsborough, RN

Management of Pediatric Tuberculosis in New Jersey

Tuberculosis. WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED

Diagnosis and Treatment of Tuberculosis, 2011

New Standards for an Old Disease:

Pathogenesis of Rheumatoid Arthritis. Smolen, J. S. et al. (2012) Nat. Rev. Rheumatol. doi: /nrrheum

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014

Didactic Series. Latent TB Infection in HIV Infection

TUBERCULOSIS. Pathogenesis and Transmission

Tuberculosis Intensive

INDEX CASE INFORMATION

Tuberculosis Populations at Risk

Treatment of Tuberculosis

TB Intensive San Antonio, Texas May 7-10, 2013

A look at medical factors that increase the risk for TB disease

A Mobile Health Intervention Utilizing Community Partnership to Improve Access to Latent Tuberculosis Infection Treatment

Drug Interactions Lisa Armitige, MD, PhD November 17, 2010

11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016

New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents

TB Intensive San Antonio, Texas. TB/HIV Co-Infection. Lisa Armitige, MD, PhD has the following disclosures to make:

Contact Investigation

The Most Widely Misunderstood Test of All

Objectives. 3HP and Flu Syndrome What is the Underlying Mechanism? Case #1 3/23/2016. Christina T. Fiske, MD MPH March 30, 2016

Tuberculosis: Where Are We Now?

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2013

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

My heart is racing. Managing Complex Cases. Case 1. Case 1

LTBI in Special Populations John Nava, MD October 5, 2010

Approaches to LTBI Diagnosis

Tuberculosis: update 2013

CHAPTER 3: DEFINITION OF TERMS

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Tuberculosis Infection in the US Military

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers

Case Management of the TB/HIV Infected Patient

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE

Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI)

Revised Technical Instructions for Civil Surgeons. October 9, 2018

Using Interferon Gamma Release Assays for Diagnosis of TB Infection

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011

TB Prevention Who and How to Screen

Latent TB Infection (LTBI) Strategies for Detection and Management

LATENT TUBERCULOSIS. Robert F. Tyree, MD

Tuberculosis and TNF Inhibitors

TB Contact Investigation

Chapter 5 Treatment for Latent Tuberculosis Infection

Tuberculosis Elimination

Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines

Tuberculosis What you need to know. James Zoretic M.D., M.P.H. Regions 2 and 3 Director

Latent Tuberculosis in Adults: From Testing TO Treatment

Interpretation of TST & IGRA results. Objectives

Treating TB What Happened? All the Patients Have Challenging Co-Morbid Conditions Now!

LTBI: Who to Test & When to Treat

Sharing the Care: Working Together on LTBI Treatment and Management Webinar. September 24, Curry International Tuberculosis Center

TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis?

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

Transcription:

LTBI Treatment and Anti TNF alpha Therapy Julie Higashi, MD PhD Director, TB Control Section San Francisco Department of Public Health TNF alpha is important for the immune response against TB Macrophages produce TNF alpha to stimulate T cells T cells produce TNF alpha to stimulate macrophages to kill tuberculosis (TB) TNF alpha and other factors induce recruitment and organized accumulation into granuloma TNF alpha blockade Granuloma breakdown, dissemination of M.tb Ehlers, et al., Clin Infect Dis, 2005 Clinical Case Woman in her 60s with mild moderate rheumatoid arthritis; candidate for anti TNF alpha therapy QuantiFERON test (QFT) positive, chest x ray (CXR) apical fibrosis LatentTB infection (LTBI) treatment with Isoniazid (INH) Rifampin (RIF) Rifabutin (RFB) Moxifloxacin (MOXI) All complicated by recurrent pruritus, no rash. Patient self discontinued multiple regimens after only a few days to weeks of treatment.

What should happen next? Proceed with anti TNF alpha therapy Rechallenge LTBI treatment Discuss options with rheumatologist Readdress treatment plan with patient What is the risk for progression to active TB on anti TNF alpha therapy? Winthrop et al., Ann Rheum Dis, 202 What is the risk for progression to active TB on anti TNF alpha therapy? Winthrop et al., Ann Rheum Dis, 202 2

Is preventive treatment for LTBI effective prior to anti TNF treatment? Patients in Spanish National Registry on anti- TNF alpha therapy treated 2002-2006 598 TST performed? 605 No Yes 4593 3573 02 Boosted TST? INH treatment 8 377 No Yes 296 Yes 950 No 56 CXR performed? 2022 68 INH treatment No Yes Yes 56 3 40 982 No 2 Chest xray compatible with past TB 634 74 INH treatment Yes 48 Gomez-Reino, et al., Arth Rheum, 2007 No 26 Effectiveness of Compliance with TB Screening and Treatment 20 Incidence rate ratio of active TB in rheumatoid arthritis population 5 0 5 0 Before 00% compliance <00% compliant vs. General Population 9.8 3 Gomez-Reino, et al., Arth Rheum, 2007 LTBI Screening and Anti TNF Alpha Therapy Screening Risk assessment (high risk vs. low risk for exposure) Screening test always Screening test and CXR if high risk for exposure to TB LTBI treatment appropriate for anyone who has history of high risk exposure regardless of screening test results Solovic, et al., Eur Resp J, 200 3

LTBI Treatment and Anti TNF Alpha Therapy Country LTBI Rx LTBI regimen Time delay before anti TNF France TST >0mm, Hx rx before 970, rx <6 m, CXR 2RZ, 3HR, 9H > 3 weeks lesions > cm 3 Germany IGRA+, abnl CXR suggestive TB without rx, 9H, 4R 2 months history of exposure Ireland TST >0mm, >5mm if immunosuppressed 9H, 4R, 4HR As long as possible after starting Rx Portugal TST >5mm, consider rx in TST neg 9H month Spain TST >5mm, abnl CXR suggestive TB without rx, hx exposure 9H month, but consider days after or concurrent Switzerland IGRA+, abnl CXR suggestive TB without rx, hx 9H, 4R month exposure UK TST >5mm, abnl CXR suggestive TB without rx, hx exposure, 6H, 3HR Abnl cxr complete rx, nl cxr, immunocompromised start concurrent USA TST+ (same cutoffs as gen pop), TST, clinical 9H Preferably complete rx or epi risks TB NET IGRA+, TST >0mm 9 2H, 3HR > 4 weeks How long do you recommend treatment for LTBI before starting anti TNF therapy? Concurrent initiation of LTBI and anti TNF alpha At least one week of LTBI treatment At least one month LTBI treatment Completion of LTBI treatment Rescreening/Retreatment Rescreening (if has diagnosis of LTBI) Yearly symptom review + CXR if never treated or symptomatic If new exposure to Mtb Retreatment for Exposure If close contact to active case, e.g., smear positive or culture positive index, would initiate treatment for LTBI Decision to complete full course of treatment rests on infectiousness of index, immune status of patient, low threshhold to complete treatment 4

Clinical Case Woman in her 60s with mild moderate rheumatoid arthritis; candidate for anti TNF alpha therapy Initiation of anti TNF alpha therapy was not urgentafter discussion with rheumatologist Recommended deferring anti TNF alpha therapy until she was ready for LTBI treatment 3HP would be our best option 5